Support for the ESMO Congress

Targeted anti-cancer therapies play a central role in oncology innovation, particularly for patients whose therapeutic needs remain insufficiently addressed. The International Congress on Targeted Anti-Cancer Therapies (TAT), organized by ESMO, is a major scientific platform bringing together researchers, clinicians, therapeutic development experts and regulatory authorities. 

In this dynamic, L’Institut Servier provides institutional support for the ESMO TAT 2026 Congress. This contribution enables the creation of an educational grant designed to facilitate the participation of twenty young researchers under the age of forty who are authors of selected abstracts. This scheme supports the presentation of their work and their active participation in the congress’s scientific exchanges. 

By supporting this initiative, L’Institut Servier reaffirms its commitment to research, training and the transmission of scientific knowledge in the service of medical progress.